Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 761-766

  Laznicek, Milan ^a   Laznickova, Alice ^a   Maecke, Helmut R ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

111In; Receptor affinity; Receptor specific distribution; Somatostatin analogs

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; DENSITY GRADIENT; DRUG DISTRIBUTION; DRUG UPTAKE; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; RAT; RECEPTOR AFFINITY;

ANIMALS; MALE; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 84858787302     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Maecke HR and Reubi JC: Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 52: 841-844, 2011.
2. Okarvi SM: Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer. Cancer Treat Rev 34: 13-26, 2008.
3. Reubi JC, Schaer J-C, Wasser S, Heppeler A, Schmitt JS and Maecke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27: 273-282, 2000. (Pubitemid 30167697)
4. Breeman WAP, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PPM, Visser TJ and Krenning EP: Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. EurJ Nucl Med 28: 1421-21429, 2001.
5. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Molec Imaging 31: 1257-1262, 2004.
6. 111In-DTPA-L-Phe1- octreotide in rats. Eur J Drug Metab Pharmacokin 27: 37-43, 2002.
7. 111In: Stability and the effect of receptor-specific binding on distribution. J Radioanal Nucl Chem 273: 587-591, 2007.
8. 111In-DOTA-TATE distribution in the target and dose-limiting tissues: Conflicting results in vitro and in vivo. Anticancer Res 28: 2189-2196, 2008.
9. Laznickova A, Laznicek M, Trejtnar F, Maecke HR, Eisenwiener KP and Reubi JC: Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats. Anticancer Res 30: 2177-2184, 2010.
10. Maecke HR and Reubi JC: Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 52: 841-844, 2011.
11. 1]-octreotide in dogs: uptake in the stomach and intestines but not in the spleen points towards interspecies differences. Nucl Med Biol 30: 225-232, 2003.
12. 0]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 46: 1561-1569, 2005.
13. Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BF, Krenning E, de Jong M, Wenger S and Reubi JC: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Molec Imaging 30: 1338-1347, 2003. (Pubitemid 37247950)
14. Froidevaux S and Eberle AN: Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66: 161-183, 2002. (Pubitemid 35285217)
15. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ and de Jong M: Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Molec Imaging 32: 1136-1143, 2005. (Pubitemid 41355939)
16. Vegt E, de Jong M, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, Gotthardt M and Boerman OC: Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51: 1049-1058, 2010.
17. Laznicek M, Laznickova A, Maecke HR, Eisenwiener K, Reubi JC and Wenger S: Octreotide and octreotate derivatives radiolabeled with yttrium: Pharmacokinetics in rats. Cancer Biother Radiopharm 17: 527-533, 2002. (Pubitemid 35231612)